Article

Pharmaceutical Executive

Pharmaceutical Executive

Pharmaceutical Executive-05-01-2006
Volume0
Issue 0

Pharm Exec 50: The World's Top 50 Pharmaceutical Companies

Changing Landscapes: A Special Report on the World?s Top 50 Pharma Companies

External Link - article-323799.pdf

Articles in this issue
More Than a Game of Keep Away
i1_t-322959-1408686481601.gif
Teamsters v. Pfizer
i1-322955-1408686490951.jpg
Leadership: It is Personal
i1-322952-1408686496191.jpg
Legal: The Kickback Effect
i1-322953-1408686494404.jpg
Washington Report: Opportunity Knocks
From the Editor: Mixed Signals
From the Editor: Mixed Signals

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Michael Grosberg
Related Content
MannKind Expands Cardiometabolic and Lung Portfolio with $360 Million Acquisition of scPharmaceuticals
August 26th 2025

MannKind Expands Cardiometabolic and Lung Portfolio with $360 Million Acquisition of scPharmaceuticals

Don Tracy, Associate Editor
The Rx for High-Performance Leadership: Cutting Through the Chaos
August 26th 2025

The Rx for High-Performance Leadership: Cutting Through the Chaos

Michael Christel
FDA Expands Indication for Amgen’s Repatha to Include Adults with High LDL-Cholesterol at Increased Risk of Major Cardiovascular Events
August 26th 2025

FDA Expands Indication for Amgen’s Repatha to Include Adults with High LDL-Cholesterol at Increased Risk of Major Cardiovascular Events

Don Tracy, Associate Editor
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 26th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
Stock.adobe.com
August 26th 2025

BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra

Nicholas Jacobus
Stock.adobe.com
August 26th 2025

Valneva Reveals FDA’s Decision to Suspend Ixchiq’s License in the U.S.

Nicholas Jacobus